Houston, Texas Downtown Skyline at Night

Angela Holmes: Improving human health

Angela Holmes, CEO of OmniScience, blends AI with life sciences for health innovation.


In brief
  • EY alumna Angela Holmes is building next-gen solutions to incorporate AI into clinical research at Houston-based OmniScience, headquartered in the Texas Medical Center.
  • She leverages her EY experience and advanced AI to transform clinical trials, precision diagnostics and digital health.
  • Her unwavering passion for mission-driven work, cultivated at Ernst & Young LLP, has shaped her into a visionary leader supporting the world’s leading biopharma companies. 

What’s the mission and focus behind OmniScience?

At OmniScience, we build AI and machine learning solutions. As computational life scientists — biomedical engineers, neuroscientists, computational biologists, biophysicists, pharmacologists,  engineers, computer scientists — we work for pharma, biotech and digital health companies to support clinical research and clinical trials to advance novel therapeutics to get treatments to patients who need them.

With the rise of generative AI, the pace of innovation in AI and life sciences is accelerating. We’re very excited about a lot of new treatments that are coming out of AI-enabled drug discovery, and our challenge — the world’s challenge — is that for all of those drugs to get to patients, they’ve got to get through clinical trials. Clinical trials have not changed in decades. Eighty percent of them come in late and over budget. They have high failure rates. We are on a mission to use AI to improve human health – but in particular, to transform how clinical trials are run, to better enable science from the data that’s captured, and lower costs and increase speed. That’s our work.


Angela Holmes, CEO of OmniScience

Angela Holmes
CEO, OmniScience

What potential do you see in how AI can help solve other challenges?

Life sciences and drug innovation require high-consequence decision-making. Clinical trials mean you are giving experimental treatments to real people. Patient safety is paramount. There’s also a tremendous amount of capital at stake in this industry — hundreds of millions to billions of dollars. There are regulatory considerations to navigate. But we’re still making a lot of decisions based on intuition because we are overwhelmed by the volume in data. Large language model (LLM) technology gives us the potential to become knowledge enabled so we can get true insights at scale, when we need them, to improve our decision-making in all forms.

 

How did your time at Ernst & Young LLP inform your career?


When I came to EY as a biomedical engineer who wanted to work on digital transformation in life sciences and health, I was impressed with the focus on teaming. In today’s global, complex, heterogenous world, you have to leverage every person’s talents and gifts and way of working. I worked with great people on top-tier teams who thought and collaborated inclusively — and always in service of the organization’s mission. Nobody was building shiny tools for the sake of shiny tools. We used the collective talent across EY, which is significant, to really transform an organization, drive its mission forward and create value.

 

Of course, I can’t forget the hours, the pressure and the travel. But even that can be memorable. Traveling and working with senior leaders very early in my career, being in the room with our clients’ leadership teams — mostly being quiet but listening and absorbing and being shaped by all those strategies — that experience has stayed with me my entire career.

 

What does the EY Alumni Network mean to you today?

I have to be honest. I was not focused on my network early on. I was very focused on my individual contributions. But I also didn’t understand that a network is not all about who you know; it’s also about what you can do and what you know that can help others. It took me a little bit longer in my career to understand the value of leveraging that network and those relationships, but it has had an immeasurable impact.

Summary 

Former EY consultant Angela Holmes is an AI strategist focused on the intersection of life sciences and technology in clinical development, precision medicine and digital health. As CEO of OmniScience, Angela is working to improve human health through her team’s unparalleled expertise in biology and data science.

About this article

Related articles

Janine Korovesis: From auditing to AI

Janine Korovesis swapped the structured world of auditing to eventually land in the dynamic landscape of Silicon Valley, now serving as vice president of finance at OpenAI. Read more.

Joy Mbanugo: EY Alumni Spotlight

Joy Mbanugo shares more about her journey from intern to executive and what energizes her in her current role as CFO of CXApp. Read more.

Geoffrey Koslov: illumination through images

This gallery owner showcases photography-based art that helps us see the world differently. Learn more.